Suppr超能文献

半夏泻心汤作为胃癌辅助治疗的疗效和安全性:系统评价和荟萃分析的方案。

Efficacy and safety of Banxia Xiexin Decoction as a complementary treatment for gastric cancer: A protocol for systematic review and meta-analysis.

机构信息

Bao'an Authentic Traditional Chinese Medicine Therapy Hospital, Shenzhen, Guangdong Province, PR China.

出版信息

Medicine (Baltimore). 2021 Apr 30;100(17):e25747. doi: 10.1097/MD.0000000000025747.

Abstract

BACKGROUND

Gastric cancer (GC) is one of the most common malignant tumors in the human digestive system, which seriously affects people's quality of life. As an effective treatment for GC, traditional Chinese medicine can effectively alleviate patients' clinical symptoms, improve the quality of life, and delay the life cycle. A large number of clinical studies have shown that Banxia Xiexin Decoction has shown a good effect in the treatment of GC. It has achieved good curative effect whether it is used alone or combined with radiotherapy and chemotherapy, which may play a more significant role in the treatment of GC. However, there is still no evidence of evidence-based medicine. Therefore, this study aims to systematically evaluate the efficacy and safety of Banxia Xiexin Decoction as a complementary treatment for GC.

METHODS

Two researchers will search the following databases: PubMed, Web of Science, MEDLINE, the Cochrane Library, Embase, China National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database, Wanfang Database, and China Biomedical Database. In addition, the Chinese Clinical Trial Register, Chinese Clinical Trial Register, conference papers, and other relevant literature will be searched manually. The retrieval time of these databases is from the establishment of the database to March 2021. The main outcome indicators of this study are the effective rate of treatment and the traditional Chinese medicine syndrome score. According to the inclusion and exclusion criteria of the literature, the data were screened and extracted. The literature quality was evaluated by the bias risk assessment tool of randomized controlled trials recommended by Cochrane Handbook, and meta-analysis was conducted RevMan 5.3 software. The Grading of Recommendations Assessment, Development, and Evaluation will be used to evaluate the quality of evidence.

RESULTS

This study will comprehensively review the existing evidence of Banxia Xiexin Decoction as a complementary in the treatment of GC.

CONCLUSION

The conclusion of this study will provide a basis for judging whether Banxia Xiexin Decoction is an effective and safe intervention for GC patients.

UNIQUE INPLASY NUMBER

INPLASY202140060.

摘要

背景

胃癌(GC)是人类消化系统中最常见的恶性肿瘤之一,严重影响人们的生活质量。作为 GC 的有效治疗方法,中药能有效缓解患者的临床症状,提高生活质量,延长生命周期。大量的临床研究表明,半夏泻心汤在 GC 的治疗中显示出良好的效果,无论是单独使用还是与放化疗联合使用,都能取得较好的疗效,可能在 GC 的治疗中发挥更显著的作用。但目前仍缺乏循证医学证据。因此,本研究旨在系统评价半夏泻心汤作为 GC 辅助治疗的疗效和安全性。

方法

两名研究人员将检索以下数据库:PubMed、Web of Science、MEDLINE、Cochrane 图书馆、Embase、中国知网、重庆维普中文科技期刊数据库、万方数据库和中国生物医学文献数据库。此外,还将手动检索中国临床试验注册中心、中国临床试验注册中心、会议论文和其他相关文献。这些数据库的检索时间从数据库建立到 2021 年 3 月。本研究的主要结局指标为治疗有效率和中医证候评分。根据文献的纳入和排除标准,筛选和提取数据。文献质量采用 Cochrane 手册推荐的随机对照试验偏倚风险评估工具进行评价,并使用 RevMan 5.3 软件进行荟萃分析。采用推荐分级的评估、制定与评价(GRADE)对证据质量进行评价。

结果

本研究将全面回顾半夏泻心汤作为 GC 辅助治疗的现有证据。

结论

本研究的结论将为判断半夏泻心汤是否为 GC 患者的有效、安全干预措施提供依据。

独特识别号

INPLASY202140060。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a7/8084055/fd118e818838/medi-100-e25747-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验